Attenuation and anticipation: A therapeutic use of lysergic acid diethylamide

LSD is described as producing profound changes in both mental and autonomic functioning, and the paper frames its therapeutic potential specifically for patients in the painful terminal stages of serious illness. Earlier clinical observation and theorising led the investigators to focus on a psychological mechanism they call anticipation — the human capacity to simulate and plan for future events through symbolic thinking and language. The authors argue that anticipation, ordinarily adaptive, can magnify suffering in situations of inescapable doom such as terminal cancer, and that attenuating anticipatory processes could reduce emotional torment. The study sets out to explore whether a single administration of LSD can therapeutically reduce suffering in pre‑terminal patients by (1) diminishing anticipatory symbolic processing through an attenuation of the power of words and concepts and (2) expanding immediate sensory experience so that present sensations gain relative prominence over future‑oriented distress. The investigators also propose mechanistic bases for analgesia under LSD, including reduction of focused attention on pain, recruitment of minor sensations to compete with major pain signals, diminished cortical control of thought, and loosening of ego boundaries that may permit the patient to dissociate from the ailing body part.

This was an open‑label, single‑dose clinical series involving 128 patients described as pre‑terminal (death anticipated within one to two months) with metastatic malignant disease. The extracted text does not clearly report the detailed diagnostic breakdown, age or sex distribution from the Table referenced. Patients were observed for at least one week before LSD administration to establish a baseline; daily visits were made by the same two observers to build a therapeutic relationship and to document pre‑treatment status. Each patient received one administration of LSD (100 meg) after breakfast. Administration took place in a pain clinic for ambulatory patients and on wards for the more severely ill. Patients were under continuous observation during the acute reaction and were then followed daily for approximately three weeks. No other analgesic medication was given during the acute LSD phase; concurrent antibiotic, cytotoxic and hormonal treatments were continued as scheduled. The investigators considered placebo control or double‑blinding impracticable because the LSD reaction is overt and immediate; instead, patients were told only that they would receive a potent medicine and might feel peculiar to reduce anticipatory fear. Outcome assessment used several clinician‑rated categorical indices. Pain intensity, affective state (depression), approach to illness and death (concernedness), sleep disturbance, visual distortions/hallucinations, and fear/panic reactions were each rated on simple ordinal scales (typically 0–2) and combined into additive cumulative indices that reflected the total burden of each parameter across the sample and over time. Observers report intuitive clinical judgements and short interviews were used rather than formal psychometric instruments. The team also experimented with co‑administration of other psychotropic drugs in some cases, noting unpredictable modification of the LSD reaction.

The primary clinical finding reported was an analgesic effect following LSD. A sharp reduction in cumulative pain scores occurred about 2–3 hours after administration; this acute pain relief lasted roughly 12 hours, while the overall total pain intensity remained reduced for a longer period, reported as about three weeks. Six deaths occurred among the patients under observation during the study period (consistent with the pre‑terminal status), but no specific adverse medical complications of LSD administration were recorded and the investigators judged LSD to be well tolerated medically. Approximately 30% of patients said they would be unwilling to repeat LSD; this unwillingness was not reduced by co‑administration of other psychotropic agents. When other drugs (chlorpromazine, MAO inhibitors, imipramine, phenobarbital, meperidine) were combined with LSD, the LSD reaction was unpredictably altered: it could be obliterated, unchanged, or rendered more distressing. The authors suggest that the latter outcome may arise when the LSD‑induced sensory input is of insufficient intensity to compete with ongoing painful input, producing annoyance rather than distraction. Affective and behavioural measures showed a transient mood elevation, described as near‑euphoria, lasting about 11–12 hours after dosing and returning to baseline thereafter. The cumulative depression index declined during the acute period. Regarding approach to illness and death, patients often displayed marked unconcern about future outcomes while still acknowledging the proximity of death; observers noted occasions when depressive signs (for example somatisation or irritability) co‑existed with an apparent lack of anticipatory concern. Sleep improved markedly on the first night after LSD and showed a meaningful reduction in sleep disturbance for up to about 10 nights. Visual phenomena were common but predominantly non‑veridical: about 55% of patients (75 individuals) reported visual distortions, while fewer than 10% experienced frank hallucinations (the extracted text gives the latter as “less than 10%”). Fear and panic were relatively uncommon: seven patients had panic reactions and 42 experienced mild anxiety. All panic or anxiety episodes were manageable with psychotherapeutic support focused on encouragement to surrender to the experience rather than resisting it. No medical adverse reactions attributable to LSD were observed. The investigators emphasise that outcome ratings were largely intuitive and presented as cumulative additive indices rather than counts of affected patients; figures and a Table are referenced in the text but not fully reproduced in the extracted material.

Ttnxley and colleagues elaborate theoretical rationales for using LSD as an analgesic and report clinical observations from a series of 128 pre‑terminal cancer patients that the drug produced acute and some sustained reductions in pain and transient improvements in mood and sleep. They note undesirable pharmacologic effects — including visual distortions and occasional panic — and report that combining LSD with other psychotropic drugs produced unpredictable alterations of the LSD reaction. The investigators state that LSD was relatively safe in this clinical context, with no adverse medical reactions observed during administration, and they recommend further study of LSD’s therapeutic potential in terminal pain and emotional distress.